| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Genome-wide association study identifies novel breast cancer susceptibility loci.
|
Nature
|
2007
|
29.23
|
|
2
|
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
|
N Engl J Med
|
2006
|
9.85
|
|
3
|
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
Nat Genet
|
2013
|
8.24
|
|
4
|
A common coding variant in CASP8 is associated with breast cancer risk.
|
Nat Genet
|
2007
|
7.35
|
|
5
|
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.
|
Nat Genet
|
2009
|
7.30
|
|
6
|
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.
|
PLoS Genet
|
2008
|
6.22
|
|
7
|
A recurrent mutation in PALB2 in Finnish cancer families.
|
Nature
|
2007
|
4.64
|
|
8
|
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
|
J Natl Cancer Inst
|
2010
|
4.54
|
|
9
|
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
|
Nat Genet
|
2013
|
4.35
|
|
10
|
Risk for distant recurrence of breast cancer detected by mammography screening or other methods.
|
JAMA
|
2004
|
4.01
|
|
11
|
Genome-wide association studies identify four ER negative-specific breast cancer risk loci.
|
Nat Genet
|
2013
|
3.81
|
|
12
|
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
|
J Clin Oncol
|
2009
|
3.63
|
|
13
|
Genome-wide association analysis identifies three new breast cancer susceptibility loci.
|
Nat Genet
|
2012
|
3.20
|
|
14
|
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.
|
J Natl Cancer Inst
|
2009
|
2.88
|
|
15
|
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.
|
Hum Mol Genet
|
2011
|
2.72
|
|
16
|
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers.
|
Am J Hum Genet
|
2013
|
2.24
|
|
17
|
A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer.
|
Cancer Res
|
2003
|
2.21
|
|
18
|
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
|
Nat Genet
|
2008
|
2.18
|
|
19
|
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
|
Clin Cancer Res
|
2003
|
2.15
|
|
20
|
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
|
Lancet Oncol
|
2009
|
1.70
|
|
21
|
Penetrance analysis of the PALB2 c.1592delT founder mutation.
|
Clin Cancer Res
|
2008
|
1.65
|
|
22
|
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.
|
Hum Mol Genet
|
2011
|
1.56
|
|
23
|
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors.
|
PLoS Genet
|
2013
|
1.56
|
|
24
|
Molecular subtypes of breast cancers detected in mammography screening and outside of screening.
|
Clin Cancer Res
|
2008
|
1.53
|
|
25
|
Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study.
|
Breast Cancer Res
|
2010
|
1.51
|
|
26
|
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.
|
BMC Clin Pathol
|
2011
|
1.46
|
|
27
|
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
|
Breast Cancer Res
|
2011
|
1.42
|
|
28
|
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.
|
Am J Hum Genet
|
2013
|
1.39
|
|
29
|
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
|
J Natl Cancer Inst
|
2013
|
1.38
|
|
30
|
Transcription factors zeb1, twist and snai1 in breast carcinoma.
|
BMC Cancer
|
2011
|
1.35
|
|
31
|
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.29
|
|
32
|
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
|
J Clin Oncol
|
2012
|
1.29
|
|
33
|
11q13 is a susceptibility locus for hormone receptor positive breast cancer.
|
Hum Mutat
|
2012
|
1.26
|
|
34
|
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.23
|
|
35
|
The role of genetic breast cancer susceptibility variants as prognostic factors.
|
Hum Mol Genet
|
2012
|
1.23
|
|
36
|
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
|
J Clin Oncol
|
2011
|
1.19
|
|
37
|
Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival.
|
J Natl Cancer Inst
|
2010
|
1.17
|
|
38
|
Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
|
Clin Cancer Res
|
2002
|
1.16
|
|
39
|
An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.16
|
|
40
|
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC).
|
PLoS One
|
2012
|
1.13
|
|
41
|
Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas.
|
Int J Cancer
|
2006
|
1.05
|
|
42
|
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium.
|
Hum Mol Genet
|
2013
|
1.00
|
|
43
|
Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
|
Clin Ther
|
2008
|
1.00
|
|
44
|
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
|
Breast Cancer Res
|
2014
|
0.99
|
|
45
|
Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection.
|
Scand J Infect Dis
|
2008
|
0.98
|
|
46
|
9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.95
|
|
47
|
Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
|
Acta Oncol
|
2008
|
0.92
|
|
48
|
Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk.
|
Pharmacogenetics
|
2004
|
0.92
|
|
49
|
Long-term prognosis of breast cancer detected by mammography screening or other methods.
|
Breast Cancer Res
|
2011
|
0.91
|
|
50
|
Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.91
|
|
51
|
Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors.
|
Int J Cancer
|
2014
|
0.90
|
|
52
|
Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes.
|
Scand J Infect Dis
|
2010
|
0.90
|
|
53
|
Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Côte d'Ivoire and Finland) with different tobacco exposure.
|
Cancer Causes Control
|
2008
|
0.90
|
|
54
|
Refinement of the 22q12-q13 breast cancer--associated region: evidence of TMPRSS6 as a candidate gene in an eastern Finnish population.
|
Clin Cancer Res
|
2006
|
0.90
|
|
55
|
Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series.
|
Eur J Cancer
|
2006
|
0.88
|
|
56
|
Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk.
|
Pharmacogenetics
|
2002
|
0.87
|
|
57
|
Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions.
|
Genet Epidemiol
|
2013
|
0.86
|
|
58
|
Pagetic bone lesions in a patient with early breast cancer--a pitfall for diagnostic misinterpretation.
|
Acta Oncol
|
2002
|
0.86
|
|
59
|
NAT2 slow acetylator genotype as an important modifier of breast cancer risk.
|
Int J Cancer
|
2005
|
0.86
|
|
60
|
XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study.
|
Breast Cancer Res
|
2005
|
0.86
|
|
61
|
A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate.
|
Int Urol Nephrol
|
2009
|
0.85
|
|
62
|
Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer.
|
Radiother Oncol
|
2006
|
0.85
|
|
63
|
ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.84
|
|
64
|
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).
|
Acta Oncol
|
2013
|
0.84
|
|
65
|
Current and predicted cost of metastatic renal cell carcinoma in Finland.
|
Acta Oncol
|
2010
|
0.83
|
|
66
|
CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population.
|
Breast Cancer Res Treat
|
2006
|
0.83
|
|
67
|
MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
|
Acta Oncol
|
2014
|
0.83
|
|
68
|
The UGT1A6_19_GG genotype is a breast cancer risk factor.
|
Front Genet
|
2013
|
0.82
|
|
69
|
Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women.
|
Pharmacogenet Genomics
|
2005
|
0.82
|
|
70
|
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.
|
PLoS One
|
2012
|
0.80
|
|
71
|
Γ-secretase components as predictors of breast cancer outcome.
|
PLoS One
|
2013
|
0.80
|
|
72
|
7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium.
|
J Med Genet
|
2011
|
0.80
|
|
73
|
SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?
|
BMC Cancer
|
2012
|
0.80
|
|
74
|
Add-on device for stereotactic core-needle breast biopsy: how many biopsy specimens are needed for a reliable diagnosis?
|
Radiology
|
2005
|
0.79
|
|
75
|
Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.
|
Int J Cancer
|
2013
|
0.79
|
|
76
|
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
|
Breast Cancer Res
|
2015
|
0.79
|
|
77
|
Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.
|
Carcinogenesis
|
2015
|
0.76
|
|
78
|
A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course.
|
Anticancer Res
|
2008
|
0.75
|
|
79
|
Effective palliation without normal tissue toxicity using low-dose ultrafractionated re-irradiation for tumor recurrence after radical or adjuvant radiotherapy.
|
Acta Oncol
|
2007
|
0.75
|
|
80
|
Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
|
Oncol Rep
|
2002
|
0.75
|
|
81
|
Radiation-induced changes in skin type I and III collagen synthesis during and after conventionally fractionated radiotherapy.
|
Radiother Oncol
|
2004
|
0.75
|